Salta al menu principale di navigazione Salta al contenuto principale Salta al piè di pagina del sito
FrancoAngeli Journals

Rubriche

N. 46 (2016)

Che cosa so di... Il ruolo della Cannabis e dei Cannabinoidi nelle malattie del fegato: review della letteratura

Inviata
21 aprile 2017
Pubblicato
21-04-2017

Abstract

In many States of USA and some Italian regions, marijuana has been legalized as medical drug.
So, a process of cannabis decriminalization is in place throughout the West.
The debate about cannabis goes on politically and socially with contrasting aspects.
Both as regards the recreational use, it should be recalled that is considered harmful (to a different extent) by virtually all the experts; both in terms of therapeutic use, considered promising by many researchers, but for which the results really sure still seem limited to a few ambit.
This paper provides a review to groped to shed light on this topic both on the legal peculiarities and medical prescribing, and especially regarding the many biological effects of cannabis and cannabinoids (the active ingredient of cannabis) on the liver.

Riferimenti bibliografici

  1. Morgante A. (2004), “Notizie storiche sulla diffusione della ‘Canapa Indiana’ tratte dalla lettura dei testi antichi”, Acta Phytotherapeutica, III, n. 3: 6-12.
  2. Russo E.B. (2007), “History of cannabis and its preparations in saga, science, and sobriquet”, Chemistry and Biodiversity, 4: 1614-1648.
  3. Booth M. (2004), Cannabis, Bantam Books, New York.
  4. Baker D., Pryce G., Giovannoni G. et al. (2003), “The therapeutic potential of
  5. cannabis”, The Lancet Neurology, 2(5): 291-298.
  6. Benigni R., Capra C., Cattorini P.E. (1962), Piante medicinali. Chimica, farmacologia e terapia, Inverni della Beffa, Milano: 206-215.
  7. Wall P. (1999), Perché proviamo dolore, Einaudi, Torino: 131-132.
  8. De Mejer E.P.M., Van der Kamp H.J. (1992), “Characterisation of Cannabis
  9. accessions with regard to cannabinoid content in relation to other caracters”,
  10. Euphytic, 62: 187-200.
  11. Radzan R.K. (1986), “Structure-activity relationships in cannabinoids”, Pharmacol Revi, 38(2): 75-149.
  12. Shoyama Y., Yagi M., Nishioka I. et al. (1975), “Biosynthesis of cannabinoid acids. Phytochemistry”, 14: 2189-2297.
  13. Mechoulam R., Shvo Y. (1963), “The structure of cannabinoid”, Tetrahedron, 19: 2073-2078.
  14. Matsuda L.A., Lolait S.J., Brownsteim M.J. et al. (1990), “Structure of a
  15. cannabinoid receptor and functional expression of the cloned cDNA”, Nature, 346: 561-564.
  16. Howlett A.C., Barth F., Bonner T.I. et al. (2002), “International Union of
  17. Pharmacology XXVII. Classification of cannabinoid receptors”, Pharmacol Rev,
  18. : 161-202.
  19. Munro S., Thomas K.L., Abu Shaar M. (1993), “Molecular characterization of a peripheral receptor for cannabinoids”, Nature, 74: 129-180.
  20. Di Marzo V., Fontana A. (1995), “Anandamide, an endogenous cannabinomimetic eicosanoid: ‘killing two birds with one stone’”, Prostaglandins Leukot Essent Fatty Acids, 53(1): 1-11.
  21. Devane W.A., Hanus L., Breuer A. et al. (1992), “Isolation and structure of a brain constituent that binds to the cannabinoid receptor”, Science, 258: 1946-1949.
  22. Mechoulam R., Ben-Shabat S., Hanus L. et al. (1995), “Identification of an
  23. endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid
  24. receptor”, Biochem Pharmacol, 50: 83-90.
  25. Piomelli D. (2003), “The molecolar logic of endocannabinoid signaling”, Nat Rev Neurosci, 4: 873-884.
  26. Hogestatt E.D., Zygmunt P.M. (2002), “Cardiovascular pharmacology of
  27. anandamide”, Prostaglandins Leukot Essent Fatty Acid, 66: 343-351.
  28. Di Marzo V., Bifulco M., De Petrocellis (2004), “The endocannabinoid system and its therapeutic exploitation”, Nat Rev Drug Discov, 3: 771-784.
  29. Compton D.R., Rice K.C., De Costa B.R. et al. (1993), “Cannabinoid
  30. structureactivity relationships: correlation of receptor binding and in vivo
  31. activies”, J Pharmacol Exp Ther, 265: 218-226.
  32. Wilson R.I., Nicoll R.A. (2002), “Endocannabinoid signaling in the brain”,
  33. Science, 296: 678-682.
  34. Huestis M.A. (2005), “Pharmacokinetic and metabolism of plant cannabinoids,
  35. Δ9-tetrahydrocannabinol, cannabidiol and cannabinol”, Handb Exp Pharmacol,
  36. : 657-690.
  37. Zaugg H.E., Kyncl J. (1983), “New antihypertensive cannabinoids”, J Med Chem, 26: 214–217. [PubMed]
  38. Lake K.D., Compton D.R., Varga K., Martin B.R., Kunos G. (1997), “Cannabinoidinduced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors”, J Pharmacol Exp Ther, 281: 1030-1037. [PubMed]
  39. Wagner J.A., Varga K., Ellis E.F., Rzigalinski B.A., Martin B.R., Kunos G. (1997), “Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock”, Nature, 390: 518-521. [PubMed]
  40. Wagner J.A., Hu K., Bauersachs J., Karcher J., Wiesler M., Goparaju S.K., Kunos G. et al. (2001), “Endogenous cannabinoids mediate hypotension after
  41. experimental myocardial infarction”, J Am Coll Cardiol, 38: 2048-2054. [PubMed]
  42. Varga K., Wagner J.A., Bridgen D.T., Kunos G. (1998), “Platelet- and macrophagederived endogenous cannabinoids are involved in endotoxin-induced
  43. hypotension”, Faseb J, 12: 1035-1044. [PubMed]
  44. Liu J., Batkai S., Pacher P., Harvey-White J., Wagner J.A., Cravatt B.F., Gao B. et al., Lipopolysaccharide induces anandamide synthesis in macrophages via
  45. CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB.
  46. Batkai S., Jarai Z., Wagner J.A., Goparaju S.K., Varga K., Liu J., Wang L. et al. (2001), “Endocannabinoids acting at vascular CB1 receptors mediate the
  47. vasodilated state in advanced liver cirrhosis”, Nat Med, 7: 827-832. [PubMed]
  48. Ros J., Claria J., To-Figueras J., Planaguma A., Cejudo-Martin P., Fernandez-Varo G., Martin-Ruiz R. et al. (2002), “Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat”, Gastroenterology, 122: 85-93. [PubMed]
  49. Biecker E., Sagesser H., Reichen J. (2004), “Vasodilator mRNA levels are increased in the livers of portal hypertensive NO-synthase 3-deficient mice”, Eur J Clin Invest, 34: 283-289. [PubMed]
  50. Domenicali M., Ros J., Fernandez-Varo G., Cejudo-Martin P., Crespo M., Morales-Ruiz M., Briones A.M. et al. (2005), “Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors”, Gut, 54: 522-527. [PMC free article] [PubMed]
  51. Moezi L., Gaskari S.A., Liu H., Baik S.K., Dehpour A.R., Lee S.S. (2006), “Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and
  52. VR(1) receptors”, Br J Pharmacol, 149: 898-908. [PMC free article] [PubMed]
  53. Yang Y.Y., Lin H.C., Huang Y.T., Lee T.Y., Hou M.C., Wang Y.W., Lee F.Y. et al. (2007), “Role of Ca2+-dependent potassium channels in in vitro anandamidemediated mesenteric vasorelaxation in rats with biliary cirrhosis”, Liver Int, 27: 1045-1055. [PubMed]
  54. Caraceni P., Viola A., Piscitelli F., Giannone F., Berzigotti A., Cescon M.,
  55. Domenicali M. et al. (2010), “Circulating and hepatic endocannabinoids and
  56. endocannabinoid-related molecules in patients with cirrhosis”, Liver Int, 30: 816-825. [PubMed]
  57. Fernandez-Rodriguez C.M., Romero J., Petros T.J., Bradshaw H., Gasalla J.M.,
  58. Gutierrez M.L., Lledo J.L. et al. (2004), “Circulating endogenous cannabinoid
  59. anandamide and portal, systemic and renal hemodynamics in cirrhosis”, Liver Int, 24: 477-483. [PubMed]
  60. Floreani A., Lazzari R., Macchi V., Porzionato A., Variola A., Colavito D., Leon A. et al. (2009), “Hepatic expression of endocannabinoid receptors and their novel polymorphisms in primary biliary cirrhosis”, J Gastroenterol. [PubMed]
  61. Bernardi M. (2002), “Renal sodium retention in preascitic cirrhosis: expanding knowledge, enduring uncertainties”, Hepatology, 35: 1544-1547. [PubMed]
  62. Domenicali M., Caraceni P., Giannone F., Pertosa A.M., Principe A., Zambruni A., Trevisani F. et al. (2009), “Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis”, Gastroenterology, 137: 341-349. [PubMed]
  63. Garcia N. Jr, Jarai Z., Mirshahi F., Kunos G., Sanyal A.J. (2001), “Systemic and portal hemodynamic effects of anandamide”, Am J Physiol Gastrointest Liver
  64. Physiol, 280: G14-20. [PubMed]
  65. Jarai Z., Wagner J.A., Varga K., Lake K.D., Compton D.R., Martin B.R., Zimmer A.M. et al. (1999), “Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors”, Proc Natl Acad Sci U S A, 96: 14136-14141. [PMC free article] [PubMed]
  66. Gaskari S.A., Honar H., Lee S.S. (2006), “Therapy insight: Cirrhotic cardiomyopathy”, Nat Clin Pract Gastroenterol Hepatol, 3: 329-337. [PubMed]
  67. Gaskari S.A., Liu H., Moezi L., Li Y., Baik S.K., Lee S.S. (2005), “Role of
  68. endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile ductligated rats”, Br J Pharmacol, 146: 315-323. [PMC free article] [PubMed]
  69. Batkai S., Mukhopadhyay P., Harvey-White J., Kechrid R., Pacher P., Kunos G. (2007), “Endocannabinoids acting at CB1 receptors mediate the cardiac
  70. contractile dysfunction in vivo in cirrhotic rats”, Am J Physiol Heart Circ Physiol,
  71. : H1689-1695. [PMC free article] [PubMed]
  72. Gebremedhin D., Lange A.R., Campbell W.B., Hillard C.J., Harder D.R. (1999),
  73. “Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit Ltype Ca2+ channel current”, Am J Physiol, 276: H2085-2093. [PubMed]
  74. Howlett A.C. (2005), “Cannabinoid receptor signaling”, Handb Exp Pharmacol: 53-79. [PubMed]
  75. Julien B., Grenard P., Teixeira-Clerc F., Van Nhieu J.T., Li L., Karsak M., Zimmer A. et al. (2005), “Antifibrogenic role of the cannabinoid receptor CB2 in the liver”, Gastroenterology, 128: 742-755. [PubMed]
  76. DeMorrow S., Francis H., Gaudio E., Ueno Y., Venter J., Onori P., Franchitto A. et al. (2008), “Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and AP-1 activation”, Am J Physiol
  77. Gastrointest Liver Physiol, 294: G506-519. [PubMed]
  78. Munoz-Luque J., Ros J., Fernandez-Varo G., Tugues S., Morales-Ruiz M., Alvarez C.E., Friedman S.L. et al. (2008), “Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats”, J Pharmacol Exp Ther, 324: 475-483. [PMC free article] [PubMed]
  79. Teixeira-Clerc F., Belot M.P., Manin S., Deveaux V., Cadoudal T., Chobert M.N., Louvet A. et al. (2010), “Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration”, Hepatology. [PMC free article] [PubMed]
  80. Hezode C., Roudot-Thoraval F., Nguyen S., Grenard P., Julien B., Zafrani E.S., Pawlotsky J.M. et al. (2005), “Daily cannabis smoking as a risk factor for
  81. progression of fibrosis in chronic hepatitis C”, Hepatology, 42: 63-71. [PubMed]
  82. Teixeira-Clerc F., Julien B., Grenard P., Tran Van Nhieu J., Deveaux V., Li L.,
  83. Serriere-Lanneau V. et al. (2006), “CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis”, Nat Med, 12: 671-676. [PubMed]
  84. Siegmund S.V., Qian T., de Minicis S., Harvey-White J., Kunos G., Vinod K.Y.,
  85. Hungund B. et al. (2007), “The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species”, Faseb J, 21: 2798-2806. [PubMed]
  86. Yang Q., Liu H.Y., Zhang Y.W., Wu W.J., Tang W.X. (2010), “Anandamide induces cell death through lipid rafts in hepatic stellate cells”, J Gastroenterol Hepatol, 25: 991-1001. [PubMed]
  87. Lotersztajn S., Teixeira-Clerc F., Julien B., Deveaux V., Ichigotani Y., Manin S., Tran-Van-Nhieu J. et al. (2008), “CB2 receptors as new therapeutic targets for liver diseases”, Br J Pharmacol, 153: 286-289. [PMC free article] [PubMed]
  88. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., Fezza F. et al.
  89. (2001), “Leptin-regulated endocannabinoids are involved in maintaining food intake”, Nature, 410: 822-825. [PubMed]
  90. Rosenson R.S. (2009), “Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk”, Cardiology, 114: 212-225. [PubMed]
  91. Tam J., Vemuri V.K., Liu J., Batkai S., Mukhopadhyay B., Godlewski G., Osei-
  92. Hyiaman D. et al. (2010), “Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity”, J Clin Invest, 120:
  93. -2966. [PMC free article] [PubMed]
  94. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Batkai S., Harvey-White J. et al. (2005), “Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity”, J Clin Invest, 115: 1298-1305. [PMC free article] [PubMed]
  95. Ravinet Trillou C., Delgorge C., Menet C., Arnone M., Soubrie P. (2004), “CB1
  96. cannabinoid receptor knockout in mice leads to leanness, resistance to dietinduced obesity and enhanced leptin sensitivity”, Int J Obes Relat Metab Disord, 28: 640-648. [PubMed]
  97. Lin J., Yang R., Tarr P.T., Wu P.H., Handschin C., Li S., Yang W. et al. (2005),
  98. “Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta
  99. coactivation of SREBP”, Cell, 120: 261-273. [PubMed]
  100. Biddinger S.B., Almind K., Miyazaki M., Kokkotou E., Ntambi J.M., Kahn C.R. (2005), “Effects of diet and genetic background on sterol regulatory elementbinding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome”, Diabetes, 54: 1314-1323. [PubMed]
  101. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. (2005), “Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease”, J Clin Invest, 115: 1343-1351.
  102. [PMC free article] [PubMed]
  103. Westerbacka J., Kotronen A., Fielding B.A., Wahren J., Hodson L., Perttila J.,
  104. Seppanen-Laakso T. et al. (2010), “Splanchnic Balance of Free Fatty Acids,
  105. Endocannabinoids, and Lipids in Subjects With Nonalcoholic Fatty Liver Disease”, Gastroenterology. [PubMed]
  106. Mukhopadhyay B., Liu J., Osei-Hyiaman D., Godlewski G., Mukhopadhyay P.,
  107. Wang L., Jeong W.I. et al. (2010), “Transcriptional regulation of cannabinoid
  108. receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptorgamma”, J Biol Chem, 285: 19002-19011. [PMC free article] [PubMed]
  109. Ruby M.A., Nomura D.K., Hudak C.S., Mangravite L.M., Chiu S., Casida J.E.,
  110. Krauss R.M. (2008), “Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins”, Proc Natl
  111. Acad Sci U S A, 105: 14561-14566. [PMC free article] [PubMed]
  112. Jourdan T., Djaouti L., Demizieux L., Gresti J., Verges B., Degrace P. (2010), “CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice”, Diabetes, 59: 926-934. [PMC free article] [PubMed]
  113. Son M.H., Kim H.D., Chae Y.N., Kim M.K., Shin C.Y., Ahn G.J., Choi S.H. et al.
  114. (2010), “Peripherally acting CB1-receptor antagonist: the relative importance of
  115. central and peripheral CB1 receptors in adiposity control”, Int J Obes (Lond), 34: 547-556. [PubMed]
  116. Quarta C., Bellocchio L., Mancini G., Mazza R., Cervino C., Braulke L.J., Fekete C. et al. (2010), “CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance”, Cell Metab, 11: 273-285. [PubMed]
  117. Hezode C., Zafrani E.S., Roudot-Thoraval F., Costentin C., Hessami A., Bouvier-Alias M., Medkour F. et al. (2008), “Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C”, Gastroenterology, 134: 432-439. [PubMed]
  118. Osei-Hyiaman D., Liu J., Zhou L., Godlewski G., Harvey-White J., Jeong W.I.,
  119. Batkai S. et al. (2008), “Hepatic CB(1) receptor is required for development of dietinduced steatosis, dyslipidemia, and insulin and leptin resistance in mice”, J Clin Invest, 118: 3160-3169. [PMC free article] [PubMed]
  120. Cota D., Marsicano G., Tschop M., Grubler Y., Flachskamm C., Schubert M., Auer D. et al. (2003), “The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis”, J Clin Invest, 112: 423-431. [PMC free article] [PubMed]
  121. Jourdan T., Djaouti L., Demizieux L., Gresti J., Verges B., Degrace P., “CB1
  122. antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice”, Diabetes, 59: 926-934. [PMC free article] [PubMed]
  123. Flamment M., Gueguen N., Wetterwald C., Simard G., Malthiery Y., Ducluzeau
  124. P.H. (2009), “Effects of the cannabinoid CB1 antagonist, rimonabant, on hepatic
  125. mitochondrial function in rats fed a high fat diet”, Am J Physiol Endocrinol Metab. [PubMed]
  126. Migrenne S., Lacombe A., Lefevre A.L., Pruniaux M.P., Guillot E., Galzin A.M.,
  127. Magnan C. (2009), “Adiponectin is required to mediate rimonabant-induced
  128. improvement of insulin sensitivity but not body weight loss in diet-induced obese mice”, Am J Physiol Regul Integr Comp Physiol, 296: R929-935. [PubMed]
  129. Watanabe T., Kubota N., Ohsugi M., Kubota T., Takamoto I., Iwabu M., Awazawa M. et al. (2009), “Rimonabant ameliorates insulin resistance via both adiponectindependent and adiponectin-independent pathways”, J Biol Chem, 284: 1803-1812. [PubMed]
  130. Watanabe T., Kubota N., Ohsugi M., Kubota T., Takamoto I., Iwabu M., Awazawa M. et al. (2009), “Rimonabant ameliorates insulin resistance via both adiponectindependent and adiponectin-independent pathways”, J Biol Chem, 284: 1803-1812. [PubMed]
  131. Herling A.W., Gossel M., Haschke G., Stengelin S., Kuhlmann J., Muller G.,
  132. Schmoll D. et al. (2007), “CB1 receptor antagonist AVE1625 affects primarily
  133. metabolic parameters independently of reduced food intake in Wistar rats”, Am J Physiol Endocrinol Metab, 293: E826-832. [PubMed]
  134. Kunz I., Meier M.K., Bourson A., Fisseha M., Schilling W. (2008), “Effects of
  135. rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean
  136. rats”, Int J Obes (Lond), 32: 863-870. [PubMed]
  137. Liu Y.L., Connoley I.P., Wilson C.A., Stock M.J. (2005), “Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice”, Int J Obes (Lond), 29: 183-187. [PubMed]
  138. Ravinet Trillou C., Arnone M., Delgorge C., Gonalons N., Keane P., Maffrand J.P., Soubrie P. (2003), “Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice”, Am J Physiol Regul Integr Comp Physiol, 284: R345-353. [PubMed]
  139. Gary-Bobo M., Elachouri G., Gallas J.F., Janiak P., Marini P., Ravinet-Trillou C.,
  140. Chabbert M. et al. (2007), “Rimonabant reduces obesity-associated hepatic
  141. steatosis and features of metabolic syndrome in obese Zucker fa/fa rats”,
  142. Hepatology, 46: 122-129. [PubMed]
  143. DeLeve L.D., Wang X., Kanel G.C., Atkinson R.D., McCuskey R.S. (2008),
  144. “Prevention of hepatic fibrosis in a murine model of metabolic syndrome with
  145. nonalcoholic steatohepatitis”, Am J Pathol, 173: 993-1001. [PMC free article]
  146. [PubMed]
  147. Wang J., Obici S., Morgan K., Barzilai N., Feng Z., Rossetti L. (2001),
  148. “Overfeeding rapidly induces leptin and insulin resistance”, Diabetes, 50: 2786-
  149. [PubMed]
  150. El-Haschimi K., Pierroz D.D., Hileman S.M., Bjorbaek C., Flier J.S. (2000), “Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity”, J Clin Invest, 105: 1827-1832. [PMC free article] [PubMed]
  151. Hollister L.E., Reaven G.M. (1974), “Delta-9-tetrahydrocannabinol and glucose tolerance”, Clin Pharmacol Ther, 16: 297-302. [PubMed]
  152. Bermudez-Siva F.J., Serrano A., Diaz-Molina F.J., Sanchez Vera I., Juan-Pico P., Nadal A., Fuentes E. et al. (2006), “Activation of cannabinoid CB1 receptors
  153. induces glucose intolerance in rats”, Eur J Pharmacol, 531: 282-284. [PubMed]
  154. Uno K., Katagiri H., Yamada T., Ishigaki Y., Ogihara T., Imai J., Hasegawa Y. et al. (2006), “Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity”, Science, 312: 1656-1659. [PubMed]
  155. Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., Zabolotny J.M., Kotani K. et al. (2005), “Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes”, Nature, 436: 356-362. [PubMed]
  156. Pagotto U., Marsicano G., Cota D., Lutz B., Pasquali R. (2006), “The emerging role of the endocannabinoid system in endocrine regulation and energy balance”, Endocr Rev, 27: 73-100. [PubMed]
  157. Bermudez-Silva F.J., Sanchez-Vera I., Suarez J., Serrano A., Fuentes E., Juan-Pico P., Nadal A. et al. (2007), “Role of cannabinoid CB2 receptors in glucose homeostasis in rats”, Eur J Pharmacol, 565: 207-211. [PubMed]
  158. Doyon C., Denis R.G., Baraboi E.D., Samson P., Lalonde J., Deshaies Y., Richard D. (2006), “Effects of rimonabant (SR141716) on fasting-induced hypothalamicpituitary-adrenal axis and neuronal activation in lean and obese Zucker rats”, Diabetes, 55: 3403-3410. [PubMed]
  159. Scheen A.J., Finer N., Hollander P., Jensen M.D., Van Gaal L.F. (2006), “Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study”, Lancet, 368: 1660-1672. [PubMed]
  160. Gonsiorek W., Lunn C., Fan X., Narula S., Lundell D., Hipkin R.W. (2005),
  161. “Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2
  162. cannabinoid receptor: antagonism by anandamide”, Mol Pharmacol, 57: 1045-
  163. [PubMed]
  164. Mendez-Sanchez N., Zamora-Valdes D., Pichardo-Bahena R., Barredo-Prieto B., Ponciano-Rodriguez G., Bermejo-Martinez L., Chavez-Tapia N.C. et al. (2007),
  165. “Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease”, Liver Int, 27: 215-219. [PubMed]
  166. Deveaux V., Cadoudal T., Ichigotani Y., Teixeira-Clerc F., Louvet A., Manin S., Nhieu J.T. et al. (2009), “Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis”, PLoS One, 4: e5844. [PMC free article] [PubMed]
  167. Lieber C.S., Schmid R. (1961), “The effect of ethanol on fatty acid metabolism; stimulation of hepatic fatty acid synthesis in vitro”, J Clin Invest, 40: 394-399. [PMC free article] [PubMed]
  168. You M., Fischer M., Deeg M.A., Crabb D.W. (2002), “Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP)”, J Biol Chem, 277: 29342-29347. [PubMed]
  169. You M., Matsumoto M., Pacold C.M., Cho W.K., Crabb D.W. (2004), “The role of AMP-activated protein kinase in the action of ethanol in the liver”,
  170. Gastroenterology, 127: 1798-1808. [PubMed]
  171. Basavarajappa B.S., Saito M., Cooper T.B., Hungund B.L. (2000), “Stimulation of cannabinoid receptor agonist 2-arachidonylglycerol by chronic ethanol and its modulation by specific neuromodulators in cerebellar granule neurons”, Biochim Biophys Acta, 1535: 78-86. [PubMed]
  172. Jeong W.I., Osei-Hyiaman D., Park O., Liu J., Batkai S., Mukhopadhyay P.,
  173. Horiguchi N. et al. (2008), “Paracrine activation of hepatic CB1 receptors by
  174. stellate cell-derived endocannabinoids mediates alcoholic fatty liver”, Cell Metab, 7: 227-235. [PubMed: 18316028]
  175. Mukhopadhyay B., Liu J., Osei-Hyiaman D., Godlewski G., Mukhopadhyay P.,
  176. Wang L., Jeong W.I. et al. (2010), “Transcriptional regulation of cannabinoid
  177. receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptorgamma”, J Biol Chem, 285: 19002-19011. [PubMed: 20410309]
  178. Jourdan T., Djaouti L., Demizieux L., Gresti J., Verges B., Degrace P., “CB1
  179. antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice”, Diabetes, 59: 926-934. [PubMed: 20110567]
  180. Avraham Y., Israeli E., Gabbay E., Okun A., Zolotarev O., Silberman I., Ganzburg V. et al. (2006), “Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice”, Neurobiol Dis, 21: 237-245. [PubMed]
  181. Dagon Y., Avraham Y., Ilan Y., Mechoulam R., Berry E.M. (2007), “Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase”, Faseb J, 21: 2431-2441. [PubMed]
  182. Avraham Y., Zolotarev O., Grigoriadis N.C., Poutahidis T., Magen I., Vorobiav L., Zimmer A. et al. (2008), “Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice”, Am J Gastroenterol, 103: 3047-3056. [PubMed]
  183. Magen I., Avraham Y., Ackerman Z., Vorobiev L., Mechoulam R., Berry E.M.
  184. (2009), “Cannabidiol ameliorates cognitive and motor impairments in mice with
  185. bile duct ligation”, J Hepatol, 51: 528-534. [PubMed]
  186. Hegde V.L.H.S., Cravatt B.F., Hofseth L.J., Nagarkatti M., Nagarkatti P.S. (2008), “Attenuation of experimental autoimmune hepatitis by exogenous and
  187. endogenous cannabinoids: involvement of regulatory T cells”, Molecular
  188. Pharmacology. [PMC free article] [PubMed]
  189. Kojima M., Kato N., Hirano D., Ochi T., Nii A., Shinjo K., Eda H. (2009), “Selective CB1 cannabinoid receptor antagonist, SR141716A, attenuates liver injury induced by Concanavalin A”, Hepatol Res, 39: 408-414. [PubMed]

Metriche

Caricamento metriche ...